Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic

AUTOR(ES)

Bueno, Fernanda; Abelleira, Erika; von Stecher, Florencia; Paes de Lima, Andrea; Pitoia, Fabián

FONTE

Arch. Endocrinol. Metab.

DATA DE PUBLICAÇÃO

2021-04

RESUMO

SUMMARY Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.

Documentos Relacionados

• Challenges in Developmental Psychology Research During the COVID-19 Pandemic
• Consideration in the management of renal cell carcinoma during the COVID-19 Pandemic
• Oncology practice during COVID-19 pandemic: a fast response is the best response
• Access to contraception during the Covid-19 pandemic: barriers and perspectives
• Emergency Surgery in Urology during the COVID-19 Pandemic